Priser
Platform
Blog
Om os
Download
BioSyent
BioSyent
TSX Venture Exchange
0

Om

Biosyent Inc. is a specialized pharmaceutical company primarily engaged in sourcing, developing, and commercializing innovative pharmaceutical products and technologies in niche areas. Established with a focus on delivering unique, health-enhancing solutions, Biosyent serves a vital role in addressing unmet medical needs. The company is particularly known for its commitment to bringing clinically proven and differentiated products to the healthcare sector, impacting areas such as women's health, cardiovascular medicine, and gastrointestinal disorders. Leveraging strategic partnerships and focused marketing, Biosyent distributes its products through a robust network catering to healthcare professionals and patients alike. Headquartered in Canada, the company plays a significant role in the pharmaceutical landscape by emphasizing safety, efficacy, and compliance in its product offerings. Its strategic approach towards niche markets enables Biosyent to maintain a competitive edge and underscores its commitment to enhancing patient and healthcare outcomes.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I BIOSYENT MED ENDAVU: Køb BioSyent ($RX) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i BioSyent, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

TickerRX
Land
Canada
Hjemmesidebiosyent.com
SektorSundhed
IndustriLægemiddelproducenter - Specialitet og generisk

Udbytter

0,16CAD
'23
0,18CAD
'24
0,2CAD
'25
0,06CAD
'26
Ex-udbytte-dato27. feb. 2026
Udbytteafkast1,4%

Analytikerskøn

Baseret på 1 analytiker

Stærkt købKøbHoldSælgStærkt sælg
100%0%0%0%0%